| 2CNX |
2.1 |
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom |
| 2CO0 |
2.25 |
WDR5 and unmodified Histone H3 complex at 2.25 angstrom |
| 2G99 |
1.9 |
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5 |
| 2G9A |
2.7 |
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5 |
| 2GNQ |
1.8 |
Structure of wdr5 |
| 2H13 |
1.58 |
Crystal structure of WDR5/histone H3 complex |
| 2H14 |
1.48 |
Crystal of WDR5 (apo-form) |
| 2H68 |
1.79 |
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex |
| 2H6K |
1.89 |
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex |
| 2H6N |
1.5 |
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex |
| 2H6Q |
1.87 |
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex |
| 2H9L |
1.75 |
WDR5delta23 |
| 2H9M |
1.9 |
WDR5 in complex with unmodified H3K4 peptide |
| 2H9N |
2.0 |
WDR5 in complex with monomethylated H3K4 peptide |
| 2H9P |
1.91 |
WDR5 in complex with trimethylated H3K4 peptide |
| 2O9K |
1.9 |
WDR5 in Complex with Dimethylated H3K4 Peptide |
| 3EG6 |
1.72 |
Structure of WDR5 bound to MLL1 peptide |
| 3EMH |
1.37 |
Structural basis of WDR5-MLL interaction |
| 3MXX |
2.05 |
Crystal structure of WDR5 mutant (S62A) |
| 3N0D |
2.3 |
Crystal structure of WDR5 mutant (W330F) |
| 3N0E |
2.5 |
Crystal structure of WDR5 mutant (W330Y) |
| 3P4F |
2.35 |
Structural and biochemical insights into MLL1 core complex assembly and regulation. |
| 3PSL |
1.7 |
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimetic |
| 3SMR |
1.82 |
Crystal structure of human WD repeat domain 5 with compound |
| 3UR4 |
1.8 |
Crystal structure of human WD repeat domain 5 with compound |
| 3UVK |
1.4 |
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 |
| 3UVL |
2.2 |
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 |
| 3UVM |
1.57 |
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 |
| 3UVN |
1.792 |
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A |
| 3UVO |
2.2 |
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B |
| 4A7J |
1.9 |
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintenance |
| 4CY1 |
1.5 |
Crystal structure of the KANSL1-WDR5 complex. |
| 4CY2 |
2.0 |
Crystal structure of the KANSL1-WDR5-KANSL2 complex. |
| 4ERQ |
1.906 |
X-ray structure of WDR5-MLL2 Win motif peptide binary complex |
| 4ERY |
1.3 |
X-ray structure of WDR5-MLL3 Win motif peptide binary complex |
| 4ERZ |
1.75 |
X-ray structure of WDR5-MLL4 Win motif peptide binary complex |
| 4ES0 |
1.817 |
X-ray structure of WDR5-SETd1b Win motif peptide binary complex |
| 4ESG |
1.7 |
X-ray structure of WDR5-MLL1 Win motif peptide binary complex |
| 4EWR |
1.503 |
X-ray structure of WDR5-SETd1a Win motif peptide binary complex |
| 4GM3 |
3.393 |
Crystal structure of human WD repeat domain 5 with compound MM-101 |
| 4GM8 |
2.601 |
Crystal structure of human WD repeat domain 5 with compound MM-102 |
| 4GM9 |
2.1 |
Crystal structure of human WD repeat domain 5 with compound MM-401 |
| 4GMB |
2.781 |
Crystal structure of human WD repeat domain 5 with compound MM-402 |
| 4IA9 |
1.66 |
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzamide |
| 4O45 |
1.87 |
WDR5 in complex with influenza NS1 C-terminal tail |
| 4QL1 |
1.5 |
Crystal structure of human WDR5 in complex with compound OICR-9429 |
| 4Y7R |
1.898 |
Crystal structure of WDR5 in complex with MYC MbIIIb peptide |
| 5EAL |
1.8 |
Crystal structure of human WDR5 in complex with compound 9h |
| 5EAM |
1.8 |
Crystal structure of human WDR5 in complex with compound 9o |
| 5EAP |
1.73 |
Crystal structure of human WDR5 in complex with compound 9e |
| 5EAR |
1.8 |
Crystal structure of human WDR5 in complex with compound 9d |
| 5M23 |
1.97 |
Modulation of MLL1 Methyltransferase Activity |
| 5M25 |
2.43 |
Modulation of MLL1 Methyltransferase Activity |
| 5SXM |
2.0 |
WDR5 in complex with MLL Win motif peptidomimetic |
| 5VFC |
1.64 |
WDR5 bound to inhibitor MM-589 |
| 6BYN |
2.69 |
Crystal structure of WDR5-Mb(S4) monobody complex |
| 6D9X |
1.83 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6DAI |
1.63 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6DAK |
1.6 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6DAR |
1.88 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6DAS |
1.8 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6DY7 |
1.9 |
WDR5 in complex with a WIN site inhibitor |
| 6DYA |
2.56 |
WDR5 in complex with a WIN site inhibitor |
| 6E1Y |
1.219 |
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design |
| 6E1Z |
1.1 |
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity |
| 6E22 |
1.6 |
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity |
| 6E23 |
1.66 |
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity |
| 6IAM |
1.51 |
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches |
| 6KIU |
3.2 |
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) |
| 6KIV |
4.0 |
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) |
| 6KIW |
4.0 |
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) |
| 6KIX |
4.1 |
Cryo-EM structure of human MLL1-NCP complex, binding mode1 |
| 6KIZ |
4.5 |
Cryo-EM structure of human MLL1-NCP complex, binding mode2 |
| 6OFZ |
1.85 |
Crystal structure of human WDR5 |
| 6OI0 |
1.92 |
Crystal structure of human WDR5 in complex with L-arginine |
| 6OI1 |
1.68 |
Crystal structure of human WDR5 in complex with monomethyl L-arginine |
| 6OI2 |
1.68 |
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-arginine |
| 6OI3 |
1.66 |
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide |
| 6PG3 |
2.04 |
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanol |
| 6PG4 |
1.6 |
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanol |
| 6PG5 |
1.99 |
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate |
| 6PG6 |
1.68 |
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamide |
| 6PG7 |
2.45 |
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanol |
| 6PG8 |
1.67 |
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanol |
| 6PG9 |
1.75 |
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamide |
| 6PGA |
2.45 |
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate |
| 6PGB |
1.73 |
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamide |
| 6PGC |
1.81 |
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate |
| 6PGD |
1.5 |
WDR5delta32 bound to peptidomimetic |
| 6PGE |
1.76 |
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoate |
| 6PGF |
1.54 |
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamide |
| 6PWV |
6.2 |
Cryo-EM structure of MLL1 core complex bound to the nucleosome |
| 6PWW |
4.4 |
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome |
| 6U5M |
1.8 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U5Y |
1.532 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U6W |
1.2 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U80 |
1.55 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U8B |
1.261 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U8L |
1.57 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6U8O |
1.6 |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protein-protein interaction |
| 6UCS |
1.85 |
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core |
| 6UFX |
2.015 |
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl]methyl}-2'-methyl[1,1'-biphenyl]-3-carboxamide (compound 13) |
| 6UHY |
1.26 |
WDR5 in complex with Myc site fragment inhibitor |
| 6UHZ |
1.258 |
WDR5 in complex with Myc site fragment inhibitor |
| 6UIF |
1.603 |
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction |
| 6UIK |
1.6 |
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction |
| 6UJ4 |
1.53 |
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction |
| 6UJH |
1.493 |
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction |
| 6UJJ |
1.731 |
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction |
| 6UJL |
1.599 |
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC interaction |
| 6UOZ |
1.532 |
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC interaction |
| 6W5I |
6.9 |
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class01) |
| 6W5M |
4.6 |
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class02) |
| 6W5N |
6.0 |
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Class05) |
| 6WJQ |
2.71 |
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 |
| 7AXP |
2.432 |
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2 |
| 7AXQ |
1.562 |
Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 K |
| 7AXS |
1.88 |
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1 |
| 7AXU |
1.68 |
Structure of WDR5:CS-VIP8 cocrystal after illumination in situ |
| 7AXX |
1.79 |
Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperature |
| 7BCY |
1.5 |
X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide |
| 7BED |
1.26 |
X-ray structure of WDR5 bound to the WDR5 win motif peptide |
| 7CFP |
1.6 |
Crystal structure of WDR5 in complex with a H3Q5ser peptide |
| 7CFQ |
1.6 |
Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide |
| 7DNO |
2.03 |
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Technique |
| 7JTO |
1.7 |
Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:ElonginC:ElonginB |
| 7JTP |
2.12 |
Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:ElonginC:ElonginB |
| 7MBM |
|
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01 |
| 7MBN |
|
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02 |
| 7Q2J |
2.5 |
Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer |
| 7U9Y |
1.9 |
WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3,4-dihydroisoquinolin-1(2H)-one |
| 7UAS |
1.808 |
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization |
| 7UD5 |
4.25 |
Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome |
| 7WVK |
1.42 |
Crystal structure of human WDR5 in complex with compound 19 |
| 8BB2 |
2.05 |
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2) |
| 8BB3 |
1.8 |
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1) |
| 8BB4 |
2.8 |
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker |
| 8BB5 |
2.2 |
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker |
| 8DU4 |
3.55 |
Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome |
| 8E9F |
1.55 |
WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-6-ethyl-N-methylquinoline-8-carboxamide (compound 10) |
| 8F1G |
2.14 |
Crystal structure of human WDR5 in complex with compound WM662 |
